The DOI matches its Crossref record; 52 of the 55 references it cites were found in a registry or an index.
Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss
Open accessAbstract
A molecular basis for memory failure in Alzheimer's disease (AD) has been recently hypothesized, in which a significant role is attributed to small, soluble oligomers of amyloid beta-peptide (A beta). A beta oligomeric ligands (also known as ADDLs) are known to be potent inhibitors of hippocampal long-term potentiation, which is a paradigm for synaptic plasticity, and have been linked to synapse loss and reversible memory failure in transgenic mouse AD models. If such oligomers were to build up in human brain, their neurological impact could provide the missing link that accounts for the poor correlation between AD dementia and amyloid plaques. This article, using antibodies raised against synthetic A beta oligomers, verifies the predicted accumulation of soluble oligomers in AD frontal cortex. Oligomers in AD reach levels up to 70-fold over control brains. Brain-derived and synthetic oligomers show structural equivalence with respect to mass, isoelectric point, and recognition by conformation-sensitive antibodies. Both oligomers, moreover, exhibit the same striking patterns of attachment to cultured hippocampal neurons, binding on dendrite surfaces in small clusters with ligand-like specificity. Binding assays using solubilized membranes show oligomers to be high-affinity ligands for a small number of nonabundant proteins. Current results confirm the prediction that soluble oligomeric A beta ligands are intrinsic to AD pathology, and validate their use in new approaches to therapeutic AD drugs and vaccines.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, recent in vivo studies have shown that soluble Aβ oligomers are more neurotoxic than amyloid plaques and most likely responsible for synaptic dysfunction and memory loss in AD.7–11”
From The effect of Cu2+ and Zn2+ on the Aβ42 peptide aggregation and cellular toxicity (2013) · cites this paper as [11]
In the citing paper
“However, recent in vivo studies have shown that the soluble Aβ oligomers are possibly more neurotoxic than amyloid plaques,14–17 and are likely responsible for synaptic dysfunction and memory loss in AD patients and AD animal models.18–21”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [18]
In the citing paper
“which was also shown to form neurotoxic soluble Aβ oligomers.18–20”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [18]
In the citing paper
“recent studies have shown that the soluble Aβ oligomers are more neurotoxic both in vitro and in vivo.5−8”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [8]
In the citing paper
“the Aβ42 peptide was employed in these studies because it was shown to form neurotoxic soluble Aβ oligomers.5,8,48”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [8]
In the citing paper
“Dot immunoblots of soluble extracts from human brain show major increases in oligomers in AD-affected tissue (Gong et al., 2003; Kayed et al., 2003; Lambert et al., 2001).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Gong et al., 2003
In the citing paper
“as have the related predictions that oligomers cause dysfunctional trafficking of ionotropic glutamate receptors and metabotropic glutamate receptors (Gong et al., 2003; Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Gong et al., 2003
In the citing paper
“Cultured hippocampal neurons incubated with brain-derived oligomers show patterns that recapitulate the in situ distribution (Gong et al., 2003).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Gong et al., 2003
In the citing paper
“Because Arc is an actin binding protein, its aberrant expression was predicted to disrupt receptor trafficking (Lacor et al., 2004), which could consequently disrupt plasticity (Gong et al., 2003).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Gong et al., 2003
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Lipid rafts and signal transduction
Simons, K., & Toomre, D. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35036052 · Cited by 5,371
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Self-citation
Research works printed but not linked: 2
- Terry R. D. (1999) in Alzheimer Disease eds. Terry R. D. Katzman R. Bick K. L. & Sisodia S. S. (Lippincott Williams & Wilkins Philadelphia) pp. 187-206.
- Chang L. Gong Y. Bakhos L. Yu J. Venton D. L. & Klein W. L. (2003) J. Mol. Neurosci. in press.
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Dhouafli, Z., Leri, M., Bucciantini, M., Stefani, M., Gadhoumi, H., Mahjoub, B., Jannet, H. B., Guillard, J., Tounsi, M. S., Ksouri, R., et al. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.04.005 · Cited by 2
Neuroprotective Function of Non-Proteolytic Amyloid-β Chaperones in Alzheimer’s Disease
Sharma, B., & Pervushin, K. V. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.84238 · Cited by 2
Different Inhibitors of Aβ42-Induced Toxicity Have Distinct Metal-Ion Dependency
Mason, A. J., Hurst, I., Malik, R., Siddique, I. A., Solomonov, I., Sagi, I., Klärner, F., Schrader, T. H., & Bitan, G. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00192 · Cited by 2
FORTIS: a live-cell assay to monitor AMPA receptors using pH-sensitive fluorescence tags
Calleja-Felipe, M., Wojtas, M. N., Diaz-González, M., Ciceri, D., Escribano, R., Ouro, A., Morales, M., & Knafo, S. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01457-w · Cited by 2
Design of Schiff Base‐derived Ligands: Applications in Therapeutics and Medical Diagnosis
Vieira, R. P., & Beraldo, H. D. O. (2014) · Wiley eBooks · doi:10.1002/9781118697191.ch7 · Cited by 2
Perspectives of Alzheimer's disease treatments
Davis, J. B., Bountra, C., & Richardson, J. C. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)01226-2 · Cited by 2
Recent progress in Alzheimer's disease: animal models lead the way
Li, T. (2004) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2004.09.002 · Cited by 2
An Individualized Approach to Treatment for Alzheimer’s Disease, Pick’s Disease, and Other Dementias
Lippa, C. F. (2006) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317506292372 · Cited by 2
Toxicity Study in Alzheimer's Disease Cell Model
Suryadi, V. R. (2014) · Cited by 2
Spectroscopic Studies of Proteins and Their Interactions with Lipids and Small Molecules
Xiong, J. (2014) · MOspace Institutional Repository (University of Missouri) · Cited by 2
Yet, L. (2018) · Wiley eBooks · doi:10.1002/9781118686263.ch5 · Cited by 2
Prangkio, P. (2011) · Deep Blue (University of Michigan) · Cited by 2
Design of non-aggregating variants of Aβ peptide
Caine, J. M., Churches, Q. I., Waddington, L. J., Nigro, J., Breheney, K., Masters, C. L., Nuttall, S. D., & Streltsov, V. A. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.09.102 · Cited by 1
Nagahama, T., Nakajima, H., Wakuta, M., Kasahara, Y., Narita, K., & Nagahama, S. (2023) · Neuroscience Research · doi:10.1016/j.neures.2023.06.004 · Cited by 1
Wang, X., Dai, L., Wu, N., Wu, D., Wang, X., Meng, X., Zhang, Q., Lu, J., Yan, X., Zhang, J., et al. (2025) · MedComm · doi:10.1002/mco2.70156 · Cited by 1
Animal Models of Alzheimer’s Disease Evaluated with [11C]Pittsburg Compound B
Burgos-Puentes, S., Avendaño‐Estrada, A., Sablón-Carrazana, M., Hernández, E. R., Granados-Juárez, A., Ramírez-Rodríguez, G. B., Meraz‐Ríos, M. A., Martínez‐Coria, H., & Avila-Rodriguez, M. A. (2026) · Life · doi:10.3390/life16010123 · Cited by 1
Dai, Y.-T., Chen, Q., Ma, Y.-D., Liu, H., Zheng, H., Zhu, Y.-Y., Gao, L., Zhao, Q., Bai, J.-L., Fan, Y.-C., et al. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.110887 · Cited by 1
Xu, Y. R., Tao, Y., Lish, A. M., Li, S., Ostaszewski, B. L., Anderson, A. K., Young‐Pearse, T. L., Lawton, T., Yang, H., Walsh, D. M., et al. (2026) · Annals of Neurology · doi:10.1002/ana.78196 · Cited by 1
Napolitano, L., Vadukul, D. M., Bigi, A., Palladino, P., Cecchi, C., Chiti, F., Cascella, R., & Aprile, F. A. (2026) · Communications Biology · doi:10.1038/s42003-026-09740-6 · Cited by 1
Neurotoxicity of the Alzheimer’s β-Amyloid Peptide
Howlett, D. R. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-888-5_6 · Cited by 1
Current status of Alzheimer’s disease immunotherapy and pharmacologic effect of BAN2401
Araki, S. (2010) · Folia Pharmacologica Japonica · doi:10.1254/fpj.136.21 · Cited by 1
Biological Targeting and Activity of Pre-fibrillar Aβ Assemblies
Wilcox, K. C., Pitt, J. E., Sebollela, A. S., Martirosova, H., Lacor, P. N., & Klein, W. L. (2011) · Springer eBooks · doi:10.1007/978-94-007-2774-8_4 · Cited by 1
Self-citationSancesario, G. (2012) · Journal of Molecular Biomarkers & Diagnosis · doi:10.4172/2155-9929.1000e107 · Cited by 1
Pathology of synapses in neurological diseases
Schwarzman, A. L., & Sarantseva, S. V. (2014) · Biology Bulletin Reviews · doi:10.1134/s2079086415020085 · Cited by 1
The role of human serum albumin in prevention and treatment of Alzheimer’s disease
Shevelyova, M. P., Deryusheva, E. I., Леонидовна, Н. Е., Валериевич, М. А., & Андреевна, Л. Е. (2023) · Журнал общей биологии · doi:10.31857/s0044459623020069 · Cited by 1
Lee, K. M., Kim, S., Tian, Y., Jung, S. M., Chang, Y., Rhee, H. Y., Park, S., Ryu, C., Lee, W.-I., Kim, E. J., et al. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1388654 · Cited by 1
Song, X., Wang, X., Gao, Y., Liu, Y., Yan, X., Xiang, Z., zhang, K., Zhao, F., Chen, Z., & Song, G. (2025) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70167 · Cited by 1
- Role of Nanocomposites and Nanostructured Biomaterials in Biomedical and Nanobiotechnology
Ahmed, A. B. A., Kumar, R. A., & Taha, R. M. (2013) · CRC Press eBooks · doi:10.1201/b14723-41 · Cited by 1
Effect of cadmium ions on amyloid beta peptide 1-42 channel activity
Notarachille, G. (2011) · Journal of Environmental Chemistry and Ecotoxicology · doi:10.5897/jece11.040 · Cited by 1
Molecular Mechanism Underlying Aβ Immunotherapy: Implications for the Toxic Action of Aβ Oligomers
Matsubara, E. (2013) · Journal of Gerontology & Geriatric Research · doi:10.4172/2167-7182.s2-001 · Cited by 1
Roy, D., Das, K., Mondal, S., Bhowmick, D., Dey, S., Majumder, G. C., Mukherjee, B., & Bhattacharyya, D. (2015) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2015.12.021 · Cited by 1
Usery, S. E. (2014) · IRL - University of Missouri, St. Louis (University of Missouri–St. Louis) · Cited by 1
Gažová, Z., Bednáriková, Z., Bartoš, A., Klaschka, J., & Krištofiková, Z. (2019) · Biomarkers in Medicine · doi:10.2217/bmm-2018-0319 · Cited by 1
Tagluk, M. E., & Işık, İ. (2020) · DÜMF Mühendislik Dergisi · doi:10.24012/dumf.703270 · Cited by 1
Physiologic and Neurotoxic Properties of Aβ Peptides
Gregory, G. C., Shepherd, C. E., & Halliday, G. M. (2006) · Springer eBooks · doi:10.1007/978-1-84628-440-3_11 · Cited by 1
Tsukakoshi, K., Kubo, R., & Ikebukuro, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314588 · Cited by 1
Animal Models for Brain Research
Dam, D. V., & Deyn, P. P. D. (2014) · Springer eBooks · doi:10.1007/978-3-642-42014-6_1 · Cited by 1
The Oligomer Species: Mechanistics and Biochemistry
Stefani, M. (2013) · Wiley eBooks · doi:10.1002/9783527654185.ch7 · Cited by 1
Bothschafter, S. (2005) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.4110 · Cited by 1
Large‐Sized Fabrication of Tunable Plasmonic Electrodes Via Electrodeposition
Chen, W., Chen, Y., Fu, S., Ko, W., & Lin, K. (2010) · Journal of the Chinese Chemical Society · doi:10.1002/jccs.201000026 · Cited by 1
Biomarkers to Advance Drug Development for Alzheimer‘s Disease
Schulman, H. (2006) · Future Neurology · doi:10.2217/14796708.1.4.409 · Cited by 1
Yeast as a Model for Studying Aβ Aggregation, Toxicity and Clearance
Bharadwaj, P. (2011) · Australasian Journal of Paramedicine · Cited by 1
Reif, B., & Narayanan, S. (2006) · Springer eBooks · doi:10.1007/128_066 · Cited by 1
Caregivers' Perceptions of an Early Diagnosis of Alzheimer's Disease in African Americans
Jackson, S. (2016) · ScholarWorks (Walden University) · Cited by 1
Nanoscale Optical Sensors Based on Surface Plasmon Resonance
Haes, A. J., Stuart, D. A., & Duyne, R. P. V. (2017) · CRC Press eBooks · doi:10.4324/9781315374581-16 · Cited by 1
Amyloid-β: less bark, more bite!
de Smith, A. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1215 · Cited by 1
Tachibana, T., & Kuwabara, T. (2019) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2019.01.006 · Cited by 1
Rye, J.-M. (2017) · theses.fr (ABES) · doi:10.70675/cf6ebbdez18d3z448azb6fczad4278aa3162 · Cited by 1
Azouz, M. (2019) · theses.fr (ABES) · doi:10.70675/4c3b6c12z1da5z497cz9e34zea6e6bf189d9 · Cited by 1
Bezine, M. (2017) · theses.fr (ABES) · doi:10.70675/a634c389z7b07z4830zb56dzbf7b53a56944 · Cited by 1
Targeting Early Stages of Alzheimer’s Disease in a Transgenic Model
Lord, A. (2009) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Reporters of Amyloid Structure
LeVine, H. (2006) · Springer eBooks · doi:10.1007/0-387-25919-8_14
Optimization of anti-Abeta antibody therapy
Karlnoski, R. (2007) · Digital Commons - University of South Florida (University of South Florida)
Wang, L., & Campioni, S. (2011) · InTech eBooks · doi:10.5772/20922
Molecular Dynamics Study of Fragmentation in Protofilaments of Amyloid Beta (16-42)
Tabatabaie-Raissi, O. (2013) · eScholarship (California Digital Library)
Alzheimer disease : Studies on Abeta and gamma-secretase in human brain
Welander, H. (2009) · Figshare
Gold nanoparticles and peptoids as novel inhibitors of Abeta aggregation in Alzheimer's disease
Moore, K. A. (2013) · Scholar Commons (University of South Carolina)
Fluorescence correlation spectroscopy: ultrasensitive detection in clear and turbid media
Tahari, A. (2006) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
Protein misfolding and amyloid formation
Nerelius, C. (2009) · Epsilon Open Archive (Sveriges lantbruksuniversitet biblioteket (Swedish University of Agricultural Sciences))
Neural stem cell biology and neurogenesis in mouse models of aging and Alzheimer's disease
Ermini, F. (2006) · edoc (University of Basel) · doi:10.5451/unibas-003819315
Effects Amyloid Beta Peptide on the Inflammatory Response in Neuronal Cells
Jang, S., Koo, H. J., Kang, S. C., Sohn, E., & Namkoong, S. (2013) · KSBB Journal · doi:10.7841/ksbbj.2013.28.4.230
Stimulating Neuroprotective and Regenerative Mechanisms in Alzheimer Disease
Lilja, A. M. (2013) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.8515
Flavonoids as Modulators of Amyloid Precursor Protein Metabolism and Alzheimer Disease Pathology
Rezai-Zadeh, K. P. (2008) · Digital Commons - University of South Florida (University of South Florida)
Role of the 39-kDa receptor-associated protein (RAP) in Alzheimer's disease
Hoang, T. (2012) · UTAS Research Repository · doi:10.25959/23206328
Hvoslef‐Eide, M. (2012) · ORCA Online Research @Cardiff (Cardiff University)
β-secretase: Physiological Role and Target Validation
Laird, F. M., Farah, M. H., Lee, H., Savonenko, A. V., Price, D. L., & Wong, P. C. (2007) · Springer eBooks · doi:10.1007/978-0-387-35135-3_4
Murtishaw, A. S. (2020) · Digital Scholarship - UNLV (University of Nevada Reno) · doi:10.34917/6456429
Delacourte, A., Campion, D., & Davous, P. (2007) · EMC - Neurologia · doi:10.1016/s1634-7072(07)70544-5 · Cited by 1
Correlati neurobiologici nell'anziano con malattia di alzheimer e altre demenze
Guaita, A. (2013) · RICERCHE DI PSICOLOGIA · doi:10.3280/rip2012-002016
Antibody Based Therapeutics for Alzheimer's Disease
Boddapati, S. P. (2011)
SPECIFIC AMYLOID-BETA OLIGOMERS IN HUMAN CEREBROSPINAL FLUID
Handoko, M. (2012) · University of Minnesota Digital Conservancy (University of Minnesota)
Davenport, R. J. (2003) · Science of Aging Knowledge Environment · doi:10.1126/sageke.2003.34.nw119
Miura, Y., & Fukuda, T. (2013) · MRS Proceedings · doi:10.1557/opl.2013.337
Amyloidkrankheiten ‐ kleine Fortschritte, große Fragen
Groß, M. (2003) · Nachrichten aus der Chemie · doi:10.1002/nadc.20030511213
Zhu, C., Xu, Y., Zhang, P., Wang, M., Liu, J., & Wu, K. (2010) · International Conference on Bioinformatics and Biomedical Technology (ICBBT) · doi:10.1109/icbbt.2010.5478934
da Silva, T. (2012) · Americanae (AECID Library)
Aβ Conformation Dependent Antibodies and Alzheimer's Disease
Sehlin, D. (2010) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Pancreatic Islet Amyloid Polypeptide Membrane Binding and Permeabilization.
Lee, E. L. (2009) · Deep Blue (University of Michigan)
Stages of Brain Functional Failure in Alzheimer’s Disease
Rapoport, S. I. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-888-5_10
Regulation of the kinesin-3 motor, KIF1A, in a cellular model of Alzheimer’s disease
Akram, A. (2016) · Summit (Simon Fraser University)
Pathogenesis of Alzheimer's Disease with Special Reference to Amyloid β Protein
Tamaoka, A. (2012) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.8.285
Fibrin Formation and Dissolution in the Progression of Amyloid-Beta Pathology in Alzheimer's Disease
Paul, J. (2025) · Digital Commons - RU (Rockefeller University) · doi:10.48496/m50g-qv97
Lee, Y. (2012) · Georgetown University-Graduate School of Arts & Sciences
Amyloid-β Protofibril Formation and Neurotoxicity : Implications for Alzheimer’s Disease
Johansson, A. (2007) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Oxidative Stress and AbetaPP Processing
Tamagno, E., & Tabaton, M. (2005) · Oxidative stress and disease · doi:10.1201/9781420026559.ch14
Luo, Y. (2008) · Oxidative stress and disease · doi:10.1201/9780849381492.ch18
The Molecular and Genetic Basis of Neurodegenerative Diseases
Tousseyn, T., Simko, J. P., Gaskin, D. A., & DeArmond, S. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3966-2.00052-7
The Current Status of Alzheimer's Disease Treatment
Lanctôt, K. L., Kircanski, I., Chau, S. A., & Herrmann, N. (2012) · Frontiers in neuroscience · doi:10.1201/b11986-5
Drugs from Molecular Targets for CNS and Neurodegenerative Diseases
Comer, W. T., & Veliçelebi, G. (2006) · CRC Press eBooks · doi:10.1201/9781420004236-16
Raman Detection in Microchips and Microchannels
Benford, M. E., Cot√©, G., Kameoka, J., & Wang, M. (2010) · CRC Press eBooks · doi:10.1201/9781420093551-c17
Preventive Effects of Resveratrol on Age-Associated Neurological Disorders
Bastianetto, S., & Quirion, R. (2012) · doi:10.1007/978-1-137-00689-9_16
Identifying the mechanism of Aβ42 inhibition of PDGF-BB signalling
Saffi, G. T. (2014) · UWSpace (University of Waterloo)
Berry, B. J. (2015) · Journal of International Crisis and Risk Communication Research
Liu, A. W. K. (2015) · TSpace (University of Toronto)
Neurochemical Aspects of β-Amyloid Cascade Hypothesis for Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00001-x · Cited by 1
Metadata
- Authors
- Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L.
- Affiliations
- Northwestern University (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2003-08-18
- Volume
- 100
- Issue
- 18
- Pages
- 10417-10422
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC193576
- OpenAlex
- W2040721710
- Cited by
- 1,061
- References
- 55
- Citations by year
- 2026: 21 · 2025: 15 · 2024: 19 · 2023: 32 · 2022: 24 · 2021: 33 · 2020: 35 · 2019: 38 · 2018: 44 · 2017: 45 · 2016: 32 · 2015: 42 · 2014: 52 · 2013: 49 · 2012: 53
- FWCI
- 35.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Northwestern University
- National Institutes of Health (1p01ag015501-01)
- National Institute on Aging (P01-AG15501, R01-AG18877, R01AG018877)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta oligomers, memory loss, hippocampal long-term potentiation, synaptic plasticity, synaptic loss, frontal cortex, dendrites, protein-ligand binding, amyloid plaques, therapeutic vaccines
- MeSH terms
- Alzheimer Disease, Animals, Binding Sites, Brain Chemistry, Cells, Cultured, Cerebral Cortex, Ligands, Neurons, Oligopeptides, Peptide Fragments, Tissue Extracts, Immunoblotting, Amyloid beta-Peptides, Rats, Sprague-Dawley, Long-Term Potentiation, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
